Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Adaptyx has demonstrated the first continuous wearable measurement of free cortisol across multiple days in humans, capturing real-time hormone dynamics rather than isolated snapshots. This shift from point-in-time testing to continuous monitoring addresses a fundamental gap in understanding how cortisol rhythms — not just absolute levels — drive metabolic health, glucose regulation, and stress resilience.
Preclinical data suggests GLP-1 therapies may accelerate late-life decline through lean mass loss and sarcopenic phenotype, particularly after treatment cessation. The research frames body composition preservation—not weight reduction alone—as central to longevity outcomes in obesity management.
Environmental chemical exposures—the exposome—now explain mortality variation better than genetics, yet remain largely unmeasured in population health studies. Systematic quantification of synthetic chemicals in biobank samples could identify disease drivers and inform large-scale risk reduction.
FibroBiologics has initiated a Phase 1/2 trial of CYWC628, a fibroblast-spheroid cell therapy applied topically to diabetic foot ulcers, enrolling up to 120 patients across Australian sites. The study will assess safety, tolerability, and efficacy compared with standard care alone, with interim analysis at six weeks to evaluate wound healing and safety endpoints.
Alnylam and Inceptive have partnered to use generative AI models to accelerate RNA interference drug design, leveraging two decades of proprietary siRNA data and six approved therapeutics. This collaboration demonstrates how machine learning can compress drug development timelines by identifying optimal molecular candidates from biological datasets, with potential applications across multiple therapeutic areas.
The Revita procedure, an endoscopic duodenal remodeling intervention, preserved 78% of GLP-1-induced weight loss one year after drug discontinuation, with one-third of participants continuing to lose weight. This addresses a clinical limitation of GLP-1 therapy: rapid weight rebound upon cessation, positioning mechanical intervention as a potential bridge to sustained metabolic change.
Magnesium functions as a central regulator of mitochondrial ATP production and metabolic resilience, with age-related declines in cellular magnesium contributing to insulin resistance, metabolic inflexibility, and accelerated aging. This positions magnesium homeostasis as a mechanistic checkpoint linking energy production capacity to disease risk and longevity.
Lifelong time-restricted feeding extended healthspan in mice on standard diets, with distinct sex-specific effects on aging pathologies and lifespan. This finding suggests temporal eating patterns influence fundamental aging processes independent of caloric restriction or weight loss.
Axo Longevity will present a data-driven preventive health platform at The Longevity Show 2026 that combines comprehensive biomarker testing, wearable metrics, and AI-powered interpretation to identify physiological changes before they become clinical problems. This represents a shift in longevity medicine from reactive treatment toward continuous monitoring and early signal detection.
The National University of Singapore has launched a Graduate Certificate in Healthy Longevity Medicine designed to train working professionals in the practical integration of geroscience, precision medicine, and clinical decision-making. The program addresses a critical gap: as longevity science accelerates toward clinical application, practitioners need formal training that bridges laboratory discovery, biomarker interpretation, and real-world implementation without overpromising or underutilizing emerging tools.
Winona established a research initiative providing funding, mentorship, and resources to early-career clinicians and trainees conducting menopause and women's health research. The program addresses a documented funding gap: women's health research received only 8.8 percent of NIH grant spending between 2013 and 2023, with that share declining over the period.
Cambrian Bio will present Phase 1b data on ATX-304, an oral small molecule combining AMPK activation with mitochondrial support, in prediabetic obese participants at the American Diabetes Association Scientific Sessions in June 2026. The compound targets metabolic sensing pathways that decline with age, addressing a significant driver of age-related cardiometabolic disease.